文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

合并症改变急性呼吸窘迫综合征的管理并恶化结局:LUNG SAFE 研究的启示

Presence of comorbidities alters management and worsens outcome of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study.
PubMed 文献 · Ann Intensive Care · 2022-05-21
一句话结论LUNG SAFE 二次分析显示,60%的 ARDS 患者至少有一种合并症,其接受的有创通气、神经肌肉阻滞、俯卧位和 ECMO 均较少,ICU 死亡率从无合并症的 27% 升至有合并症的 39%。

该研究为 LUNG SAFE 研究的二次分析,纳入 2813 例 ARDS 患者,旨在明确合并症对管理及 ICU 生存的影响。1692 例(60%)至少有一种合并症,其中慢性呼吸功能受损 631 例(22.4%)、免疫缺陷 584 例(20.8%)、糖尿病 613 例(21.8%)等。有合并症者接受有创通气(82% vs 89%)、神经肌肉阻滞(18% vs 22%)、俯卧位(6% vs 9%)和 ECMO(2% vs 4%)的比例均显著低于无合并症者。ICU 死亡率从无合并症的 27%(n=303)升至有合并症的 39%(n=661),充血性心力衰竭、慢性肝衰竭和免疫缺陷各自独立与 ICU 死亡率升高相关。

要点

  • 2813 例 ARDS 患者中 1692 例(60%)至少有一种合并症,423 例(25%)有两种,182 例(11%)有三种及以上。
  • 有合并症者接受有创通气 82% vs 无合并症者 89%、神经肌肉阻滞 18% vs 22%、俯卧位 6% vs 9%、ECMO 2% vs 4%,均显著减少。
  • ICU 死亡率无合并症者 27%(n=303),有合并症者 39%(n=661)。
  • 充血性心力衰竭、慢性肝衰竭和免疫缺陷各自独立与 ICU 死亡率升高相关。
  • 慢性肝衰竭和免疫缺陷独立与更多限制生命支持措施的决定相关。

适用人群与场景

  • LUNG SAFE 研究队列中的 ARDS 患者,共 2813 例。

研究设计与关键结果

  • 研究类型:LUNG SAFE 研究入组患者队列的二次分析。
  • 合并症分布:1692 例(60%)有至少 1 种合并症;慢性呼吸功能受损 631 例(22.4%)、充血性心力衰竭 290 例(10.3%)、慢性肾衰竭 286 例(10.2%)、慢性肝衰竭 112 例(4%)、免疫缺陷 584 例(20.8%)、糖尿病 613 例(21.8%)。
  • 多种合并症:423 例(25%)有 2 种合并症,182 例(11%)有至少 3 种合并症。
  • 有合并症 vs 无合并症(1692 例 vs 1121 例,60% vs 40%):有创通气 1379 例(82%)vs 998 例(89%)、神经肌肉阻滞 301 例(18%)vs 249 例(22%)、俯卧位 97 例(6%)vs 104 例(9%)、ECMO 32 例(2%)vs 46 例(4%),均有合并症组显著减少。
  • ICU 死亡率:无合并症者 27%(n=303),有合并症者 39%(n=661)。
  • 充血性心力衰竭、慢性肝衰竭和免疫缺陷各自独立与 ICU 死亡率升高相关;慢性肝衰竭和免疫缺陷独立与更多限制生命支持措施的决定相关。

证据类型、等级与局限

  • 证据类型:LUNG SAFE 研究队列的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,多数 ARDS 患者有显著合并症,他们接受较少积极治疗且结局更差。
  • 作者认为,改善这些患者的治疗必须成为未来临床研究的优先事项。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The impact of underlying comorbidities on the clinical presentation, management and outcomes in patients with ARDS is poorly understood and deserves further investigation.

OBJECTIVES: We examined these issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study.

METHODS: In this secondary analysis of the patient cohort enrolled in the LUNG SAFE study, our primary objective was to determine the frequency, and impact of comorbidities on the management and ICU survival of patients with ARDS. Secondary outcomes relating to comorbidities included their impact on ventilatory management, the development of organ failures, and on end-of-life care.

RESULTS: Of 2813 patients in the study population, 1692 (60%) had 1 or more comorbidities, of whom 631 (22.4%) had chronic respiratory impairment, 290 (10.3%) had congestive heart failure, 286 (10.2%) had chronic renal failure, 112 (4%) had chronic liver failure, 584 (20.8%) had immune incompetence, and 613 (21.8%) had diabetes. Multiple comorbidities were frequently present, with 423 (25%) having 2 and 182 (11%) having at least 3 or more comorbidities. The use of invasive ventilation (1379 versus 998, 82 versus 89%), neuromuscular blockade (301 versus 249, 18 versus 22%), prone positioning (97 versus 104, 6 versus 9%) and ECMO (32 versus 46, 2 versus 4%) were each significantly reduced in patients with comorbidities as compared to patients with no comorbidity (1692 versus 1121, 60 versus 40%). ICU mortality increased from 27% (n = 303) in patients with no comorbidity to 39% (n = 661) in patients with any comorbidity. Congestive heart failure, chronic liver failure and immune incompetence were each independently associated with increased ICU mortality. Chronic liver failure and immune incompetence were independently associated with more decisions to limitation of life supporting measures.

CONCLUSIONS: Most patients with ARDS have significant comorbidities, they receive less aggressive care, and have worse outcomes. Enhancing the care of these patients must be a priority for future clinical studies. Trial registration LUNG-SAFE is registered with ClinicalTrials.gov, number NCT02010073.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Rezoagli E, McNicholas BA, Madotto F, et al. Presence of comorbidities alters management and worsens outcome of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study. Ann Intensive Care. 2022. PMID: 35596885. doi:10.1186/s13613-022-01015-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。